Pioneering Drug Delivery Technologies
Through a growth-oriented business strategy, and powered by our advanced formulation expertise and unique drug delivery technologies, we are a leader in the development, manufacturing and marketing of specialty prescription pharmaceutical products.
We currently manufacture and market 102 generic pharmaceutical products, which represent dosage variations of 30 different pharmaceutical compounds through our Global Pharmaceuticals Division; another 16 of our generic pharmaceutical products representing dosage variations of four different pharmaceutical compounds are marketed by our alliance agreement partners.
We have a good track record of performance with 66 ANDAs approved by the FDA, and we currently market 43 of these.
Global Pharmaceuticals' state-of-the-art facilities and distribution centers provide the foundation for our success in delivering products to our customers and partners worldwide.
Combined with the research and drug delivery expertise of our parent company, Impax Laboratories, Global Pharmaceuticals' product line has become a major source of generic medications globally.
Our current generic pipeline has never been more valuable than it is today with more first-to-file and first-to-market opportunities either pending or under development than ever before. We currently have 39 pending ANDAs with at least 7 ANDAs having first-to-file or first-to-market potential. The following lists our disclosed pending pipeline.
We are also working on an additional 79 products under development with many having the potential to be first-to-file or first-to-market opportunities. For 2011, our internal/external goal is to file at least 12 new applications with at least 3 of these being first-to-file or first-to-market opportunities.